Since its establishment, based on its own characteristics, the Company has been cultivating intensively with the pragmatic and innovative striver’s spirit. At present, it has obtained accumulatively 70 drug production and registration approvals (including 22 marketed first generic drugs, the rate of marketed first generic drug exceeds 31%, and the success rate of marketed first generic drug is at the leading level in the industry), of which, the technology of some varieties has been transferred to multiple well-known domestic pharmaceutical enterprises in China, creating good social and economic benefits. Currently, the Company is selling 49 varieties (including 3 varieties to be marketed), mainly in the therapeutic fields such as digestive tract and metabolism, blood and hematopoietic system, systemic anti-infection, cardiovascular system, nervous system (including anesthesia), and dermatology.

The Company has applied accumulatively for 570 patents (including 562 patents for invention, 6 for utility model and 2 for appearance) and 118 applications for PCT, and has obtained 231 licenses (223 for invention patents, 6 for utility model and 2 for appearance), among which, the patents for Polyene Phosphatidylcholine Injection and its preparation method have won the Chinese Patent Excellence Award; the Company has applied accumulatively for 661 trademarks and obtained 548 authorizations.